Table 3.

Correlations among catecholamine metabolites in plasma and urine, scales for third-party assessment, and subjective assessment of some aspects of the mental condition

	HVA (plasma)	5-HIAA (plasma)	MHPG (plasma)	HVA (urine)	5-HIAA (plasma)	VMA (urine)
PANNS total
r	0.51**	NS	NS	NS	NS	NS
P	<0.001**,#
R2	0.27
BCa 95% CI	0.25–0.70
PANSS cognitive
r	0.49	NS	NS	0.30	NS	NS
P	0.001**,#			0.045*
R2	0.26			0.09
BCa 95% CI	0.32–0.66			−0.01 to 0.15
PANSS depressive
r	0.37	NS	NS	NS	NS	NS
P	0.01*
R2	0.14
BCa 95% CI	0.02–0.63
HRSD
r	0.39	NS	NS	NS	NS	NS
P	0.007*
R2	0.15
BCa 95% CI	0.17–0.61
BDI
r	0.313	NS	NS	NS	NS	NS
P	0.03
R2	0.09
BCa 95% CI	0.004–0.57
VAS ability to concentrate
r	−0.48	−0.36	NS	NS	NS	NS
P	0.001**,#	0.015*
R2	0.23
BCa 95% CI	−0.65 to −0.31	−0.53 to −0.20
VAS general well-being
r	−0.44	−0.46	NS	NS	NS	NS
P	0.002**,#	0.002**,#
R2	0.19	0.21
BCa 95% CI	−0.64 to 0.22	−0.62 to −0.3
VAS fatigue
r	0.37	NS	NS	NS	NS	NS
P	0.011*
R2	0.14
BCa 95% CI	0.14–0.61
VAS motivation
r	NS	NS	NS	NS	NS	NS
P
R2
BCa 95% CI
VAS drive
r	−0.34	NS	NS	NS	NS	NS
P	0.021*
R2	0.12
BCa 95% CI	−0.62 to −0.05

Notes:

^*P<0.05;

^**P<0.01;

^**,#correlations remaining significant after Bonferroni correction (corrected significance level for ten scores and six metabolites P=0.003). Scales for third-party assessment (PANSS and HRSD) and assessment of mental condition (VAS and BDI) in the verum group measured on day 8 (24 hours after cessation of antidopaminergic intervention). PANSS subscales defined by the Lindenmayer et al model⁵² were analyzed separately.

Abbreviations: HVA, homovanillic acid; RM ANOVA, repeated-measures analysis of variance; HIAA, hydroxyindoleacetic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; VMA, vanillylmandelic acid; PANSS, Positive and Negative Syndrome Scale; HRSD, Hamilton Rating Scale for Depression; VAS, visual analogue scale; BDI, Beck Depression Inventory; BC_a, bias corrected and accelerated; NS, not significant.